Key Points
- Incyte insider Thomas Tray sold 610 shares for $72,565.60 under a pre-arranged Rule 10b5-1 plan, retaining 21,126 shares after the sale.
- Incyte reported quarterly revenue of $1.56 billion, up 14% year over year, and EPS of ($3.60), which beat analysts’ estimate of ($3.93).
- Investors are watching new hematology pipeline data expected at ASH 2026; Canaccord maintained a Buy rating and $152 target, while analysts’ consensus rating was Hold with an average $132.86 target.
Incyte Corporation (NASDAQ:INCY - Get Free Report) insider Thomas Tray sold 610 shares of the company's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the sale, the insider owned 21,126 shares of the company's stock, valued at $2,513,148.96. This trade represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Incyte Stock Performance
Shares of NASDAQ INCY opened at $118.01 on Friday. Incyte Corporation has a 1 year low of $89.25 and a 1 year high of $132.60. The firm has a market cap of $24.05 billion, a P/E ratio of 57.95, a PEG ratio of 4.47 and a beta of 0.78. The stock has a fifty day moving average price of $119.78 and a two-hundred day moving average price of $108.42.
Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter in the previous year, the business earned $2.26 EPS. The company's quarterly revenue was up 14.0% compared to the same quarter last year. On average, research analysts predict that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.
Incyte News Roundup
Here are the key news stories impacting Incyte this week:
- Positive Sentiment: Canaccord Genuity maintained its Buy rating and $152 price target, citing upcoming ASH 2026 data for ’989 as supportive of its view. Article
- Positive Sentiment: Incyte plans to present new data across its hematology portfolio at ASH 2026. The results could provide investors with updates on its pipeline and future growth prospects. Article
- Neutral Sentiment: Incyte sued a generic drug manufacturer over patents for a blood-cancer treatment. Protecting patent rights could help defend product revenue, although litigation outcomes and timing are uncertain. Article
- Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, a small portion of his holdings. The planned sale may be less informative than an unplanned transaction. SEC filing
- Negative Sentiment: Leerink Partners lowered its price target to $150 from $154, though it kept an Outperform rating—still signaling substantial potential upside from the cited share price. Article
Wall Street Analysts Forecast Growth
INCY has been the topic of a number of research analyst reports. TD Cowen boosted their price target on shares of Incyte from $138.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, October 21st. BMO Capital Markets restated a "market perform" rating on shares of Incyte in a research report on Tuesday, October 27th. Benchmark restated a "buy" rating on shares of Incyte in a research report on Tuesday, October 13th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Incyte in a research note on Friday, September 11th. Finally, Morgan Stanley assumed coverage on shares of Incyte in a report on Tuesday, October 20th. They issued an "equal weight" rating and a $119.00 target price on the stock. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Incyte presently has a consensus rating of "Hold" and an average target price of $132.86.
View Our Latest Analysis on INCY
Institutional Investors Weigh In On Incyte
Several large investors have recently modified their holdings of INCY. Trails Edge Capital Partners LP purchased a new stake in shares of Incyte during the second quarter valued at $17,570,800. Twin Capital Management Inc. acquired a new position in shares of Incyte in the 1st quarter valued at $875,000. Tidal Investments LLC boosted its position in shares of Incyte by 33.4% in the 2nd quarter. Tidal Investments LLC now owns 102,834 shares of the biopharmaceutical company's stock valued at $11,657,000 after purchasing an additional 25,768 shares during the period. BlackRock Inc. purchased a new position in Incyte in the 2nd quarter worth about $2,044,189,000. Finally, Mediolanum International Funds Ltd increased its stake in Incyte by 25.4% in the 1st quarter. Mediolanum International Funds Ltd now owns 60,300 shares of the biopharmaceutical company's stock worth $5,447,000 after purchasing an additional 12,227 shares in the last quarter. 96.97% of the stock is owned by institutional investors.
Incyte Company Profile
(
Get Free Report)
Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.
Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
